Page last updated: 2024-08-18

4-butyrolactone and Carcinoma, Non-Small Cell Lung

4-butyrolactone has been researched along with Carcinoma, Non-Small Cell Lung in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bai, J; Ding, X; Jiang, X; Qian, M; Wu, H; Zhang, X; Zhao, W; Zhu, F	1
Bidoli, P; Cho, BC; Chouaid, C; Corral Jaime, J; Dennis, PA; Garassino, MC; Gray, JE; Huang, Y; Kim, JH; Lena, H; Mazières, J; Park, K; Powderly, J; Rizvi, NA; Soo, RA; Vansteenkiste, J; Wadsworth, C; Wheatley-Price, P	1
Burlison, JA; Li, C; Lu, H; Machen, TE; Neely, AM; Schwarzer, C; Stivers, NS; White, C; Whitt, AG; Zhao, G	1
Chen, CY; Chen, YY; Hsu, YL; Huang, MS; Hung, JY; Kuo, PL	1

Trials

1 trial(s) available for 4-butyrolactone and Carcinoma, Non-Small Cell Lung

Article	Year
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet. Oncology, 2018, Volume: 19, Issue:4 Topics: 4-Butyrolactone; Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Aspartate Aminotransferases; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Fatigue; Female; gamma-Glutamyltransferase; Humans; Injection Site Reaction; Lung Neoplasms; Male; Middle Aged; Mutation; Pneumonia; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors	2018

Article

Year

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

The Lancet. Oncology, 2018, Volume: 19, Issue:4

Topics: 4-Butyrolactone; Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Aspartate Aminotransferases; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Fatigue; Female; gamma-Glutamyltransferase; Humans; Injection Site Reaction; Lung Neoplasms; Male; Middle Aged; Mutation; Pneumonia; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors

2018

Other Studies

3 other study(ies) available for 4-butyrolactone and Carcinoma, Non-Small Cell Lung

Article	Year
Ligustilide inhibits the proliferation of non-small cell lung cancer via glycolytic metabolism. Toxicology and applied pharmacology, 2021, 01-01, Volume: 410 Topics: 4-Butyrolactone; A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Glycolysis; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation	2021
N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins. Oncotarget, 2016, Feb-02, Volume: 7, Issue:5 Topics: 4-Butyrolactone; Animals; Apoptosis; Aryldialkylphosphatase; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Female; Flow Cytometry; Fluorescent Antibody Technique; Homoserine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2016
Isokotomolide A, a new butanolide extracted from the leaves of Cinnamomum kotoense, arrests cell cycle progression and induces apoptosis through the induction of p53/p21 and the initiation of mitochondrial system in human non-small cell lung cancer A549 c European journal of pharmacology, 2007, Nov-28, Volume: 574, Issue:2-3 Topics: 4-Butyrolactone; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Lung Neoplasms; Mitochondria; Tumor Suppressor Protein p53	2007